Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis

Molecular Imaging

Volumn 7, Issue 2, 2008, Pages 68-76

  Graf, Kristof ^a   Dietrich, Thore ^b   Tachezy, Michael ^b   Scholle, Frank Detlef ^b   Licha, Kai ^b   Stawowy, Philipp ^b   Grafe, Michael ^b   Hauff, Peter ^b   Fleck, Eckart ^b  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROTIC LESIONS; CHOLESTEROL ABSORPTIONS; EX-VIVO; EZETIMIBE; IMMUNOHISTOCHEMISTRY; IN-VIVO; INTRAVENOUS APPLICATIONS; LESION FORMATIONS; MATRIX PROTEINS; NEAR-INFRARED FLUORESCENCE IMAGING; NEAR-INFRARED FLUORESCENCES;

BLOOD VESSELS; FLUORESCENCE;

INFRARED DEVICES;

APOLIPOPROTEIN E; AZETIDINE DERIVATIVE; ED B FIBRONECTIN PROTEIN, MOUSE; ED-B FIBRONECTIN PROTEIN, MOUSE; EZETIMIBE; FIBRONECTIN; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL; AORTA; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; C57BL MOUSE; DIAGNOSTIC IMAGING; DISEASE MODEL; GENETICS; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; NEAR INFRARED SPECTROSCOPY; PATHOLOGY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; AZETIDINES; DIAGNOSTIC IMAGING; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; FIBRONECTINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPECTROSCOPY, NEAR-INFRARED;

EID: 55749087351     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2008.0009     Document Type: Article

References (33)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Fayad ZA, Sirol M, Nikolaou K, et al. Magnetic resonance imaging and computed tomography in assessment of atherosclerotic plaque. Curr Atheroscler Rep 2004;6:232-42.
3. Choi SH, Chae A, Chen CH, et al. Emerging approaches for imaging vulnerable plaques in patients. Curr Opin Biotechnol 2007;18:73-82.
4. MacNeill BD, Lowe HC, Takáno M, et al. Intravascular modalities for detection of vulnerable plaque: current status. Arterioscler Thromb Vase Biol 2003;23:1333-42.
5. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
6. Botnar RM, Perez AS, Witte S, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004;109:2023-9.
7. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003;108:2270-4.
8. Matter CM, Schuler PK, Alessi P, et al. Molecular imaging of atherosderotic plaques using a human antibody against the extradomain B of fibronectin. Circ Res 2004;95:1225-33.
9. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006;114:1504-11.
10. Deguchi JO, Aikawa M, Tung CH, et al. Inflammation in atherosderosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006;114:55-62.
11. Chen J, Tung CH, Mahmood U, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002;105:2766-71.
12. Dietrich T, Perlitz C, Licha K, et al. ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions. Basic Res Cardiol 2007;102:298-307.
13. Glukhova MA, Frid MG, Shekhonin BV, et al. Expression of fibronectin variants in vascular and visceral smooth muscle cells in development. Dev Biol 1990;141:193-202.
14. Dubin D, Peters JH, Brown LF, et al. Balloon catheterization induced arterial expression of embryonic fibronectins. Arterioscler Thromb Vase Biol 1995;15:1958-67.
15. Altmann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4.
16. Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004;279:33586-92.
17. Davis HR Jr, Compton DS, Hoos L, et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001;21:2032-8.
18. Davis HR Jr, Hoos LM, Tetzloff G, et al. Deficiency of NiemannPick Cl Like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler Thromb Vasc Biol 2007;27:841-9.
19. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-76.
20. National Institutes of Health. Guide for the care and use of laboratory animals. Bethesda (MD): National Institutes of Health; 1996; NIH Publication No.: 85-23.
21. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995;36:2320-8.
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-10.
23. Ntziachristos V, Schellenberger EA, Ripoll J, et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A 2004;101:12294-9.
24. Matter CM, Wyss MT, Meier P, et al. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol 2006;26:584-9.
25. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PETCT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008;117:379-87.
26. Chu B, Hatsukami TS, Polissar NL, et al. Determination of carotid artery atherosclerotic lesion type and distribution in hypercholesterolemic patients with moderate carotid stenosis using noninvasive magnetic resonance imaging. Stroke 2004;35:2444-8.
27. Saam T, Ferguson MS, Yarnykh VL, et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler Thromb Vasc Biol 2005;25:234-9.
28. Frias JC, Williams KJ, Fisher EA, et al. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004;126:16316-7.
29. Mulder WJ, Strijkers GJ, Briley-Saboe KC, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEGmicelles. Magn Reson Med 2007;58:1164-70.
30. Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic partides of iron oxide in hyperlipidemic rabbits. Circulation 2001;103:415-22.
31. Sosnovik DE, Nahrendorf M, Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 2007; 115:2076-86.
32. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosderotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107:2453-8.
33. Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005;9:491-500.